Scarica l'app Stockscreener
4.53
0.88%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.57
Aprire:
$4.62
Volume 24 ore:
3.89M
Relative Volume:
0.81
Capitalizzazione di mercato:
$567.30M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-2.7622
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-6.98%
1M Prestazione:
+12.97%
6M Prestazione:
+21.12%
1 anno Prestazione:
-27.29%
Intervallo 1D:
$4.53
$4.75
Intervallo di 1 settimana:
$4.47
$4.96
Portata 52W:
$2.90
$7.73
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.53 | 572.31M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 286% Upside In Biotechnology - DirectorsTalk Interviews
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - TipRanks
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Altimmune closes $75 million registered direct offering By Investing.com - Investing.com India
Altimmune (NASDAQ:ALT) Trading Up 7.2%Here's What Happened - MarketBeat
Is Altimmune Inc. a potential multi baggerAnalyst Upgrade & High Accuracy Trade Signal Alerts - mfd.ru
Altimmune closes $75 million registered direct offering - Investing.com
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Benzinga
Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial - Stock Titan
Altimmune (NASDAQ:ALT) Rating Increased to Strong-Buy at Barclays - MarketBeat
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Sahm
Altimmune raises $75 million to fund MASH therapy development By Investing.com - Investing.com Nigeria
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits
Altimmune Announces $75 Million Registered Direct Equity Offering - TipRanks
Altimmune Signs Multiple Material Agreements - TradingView
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
Altimmune prices $75M direct offering - MSN
Altimmune (NASDAQ:ALT) Shares Gap DownHere's Why - MarketBeat
Altimmune Stock Volatility Spurs Investor Attention - StocksToTrade
Altimmune’s Recent Developments and Market Impact - timothysykes.com
Altimmune shares slide after $75 million registered direct offering - MSN
Altimmune stock falls after announcing $75 million direct offering By Investing.com - Investing.com South Africa
Altimmune stock falls after announcing $75 million direct offering - Investing.com
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Altimmune Prices $75 Million Registered Direct Offering - marketscreener.com
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline - TipRanks
Altimmune Prices $75 Mln Of Share Offering; Stock Down - Nasdaq
Altimmune (ALT) Prepares for Phase 3 Trial with New Funding - GuruFocus
Altimmune Secures $75M from Institutional Investor in Direct Offering - Intellectia AI
Altimmune (ALT) Secures $75M in Direct Offering to Fund Phase 3 Trial - GuruFocus
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Trend Recap: Will Altimmune Inc stock hit new highs in YEAR - baoquankhu1.vn
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Altimmune Inc Azioni (ALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
57,770 |
| Garg Vipin K | Director |
Jan 25 '26 |
Option Exercise |
0.00 |
42,050 |
0 |
397,132 |
| Roberts M Scot | Chief Scientific Officer |
Jan 25 '26 |
Option Exercise |
0.00 |
14,600 |
0 |
88,666 |
| Pisano Wayne | Director |
Jan 08 '26 |
Buy |
4.08 |
5,000 |
20,410 |
13,498 |
| Jordt Raymond M | Chief Business Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
9,375 |
0 |
45,645 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):